Chris Viehbacher, Glaxo's president of U.S. pharmaceuticals, said this in a telephone interview with Reuters :"If you believe there is a risk, it applies to everybody," Viehbacher said. "It wouldn't be fair to just put labeling on Avandia. We know there is a class effect on the heart failure piece. There may be one on the ischemic side as well."
The "everybody" mentioned here preseumably means Actos, the other glitazone.
Insider's view: Hmmm. Insider was taught that "heart failure" was not a diagnosis and the cause should be searched for.
Such as ischaemia, for example.
No comments:
Post a Comment